New injection shows promise for tough eczema in early trial
NCT ID NCT07502222
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 study tests a new biologic drug called AK139 in 168 adults with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with creams. Participants will receive either AK139 or a placebo by injection. The study aims to see if AK139 can safely clear skin and reduce itching.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AK139 (a biologic drug given by injection)
- What this could lead to
- If it works, this could point toward a new treatment option for people with moderate-to-severe eczema that doesn't respond to creams.
- What could go wrong
- This is an early Phase 2 trial with only 168 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE-TO-SEVERE ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill tame tough eczema? a large trial aims to find out
- New shot could tame tough eczema by calming overactive immune cells
- New drug aims to calm severe eczema without steroids
- New drug shows promise for severe eczema in toddlers
- Eczema drug nemolizumab put to the vaccine test
- New shot could tame severe eczema in kids